IL85897A0 - Method of diagnosing obesity caused by a genetic abnormality - Google Patents

Method of diagnosing obesity caused by a genetic abnormality

Info

Publication number
IL85897A0
IL85897A0 IL85897A IL8589788A IL85897A0 IL 85897 A0 IL85897 A0 IL 85897A0 IL 85897 A IL85897 A IL 85897A IL 8589788 A IL8589788 A IL 8589788A IL 85897 A0 IL85897 A0 IL 85897A0
Authority
IL
Israel
Prior art keywords
genetic abnormality
adipsin
obesity caused
abnormality
diagnosing obesity
Prior art date
Application number
IL85897A
Other languages
English (en)
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Publication of IL85897A0 publication Critical patent/IL85897A0/xx

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/044Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL85897A 1987-04-02 1988-03-29 Method of diagnosing obesity caused by a genetic abnormality IL85897A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3420387A 1987-04-02 1987-04-02

Publications (1)

Publication Number Publication Date
IL85897A0 true IL85897A0 (en) 1988-09-30

Family

ID=21874944

Family Applications (1)

Application Number Title Priority Date Filing Date
IL85897A IL85897A0 (en) 1987-04-02 1988-03-29 Method of diagnosing obesity caused by a genetic abnormality

Country Status (13)

Country Link
EP (2) EP0382720B1 (de)
JP (1) JPH02503229A (de)
AT (1) ATE80465T1 (de)
AU (1) AU606946B2 (de)
DE (1) DE3874543T2 (de)
DK (1) DK675388A (de)
ES (1) ES2046325T3 (de)
FI (1) FI894592A0 (de)
GR (1) GR3005716T3 (de)
IL (1) IL85897A0 (de)
NO (1) NO885360L (de)
WO (1) WO1988007681A1 (de)
ZA (1) ZA882288B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2084062A1 (en) * 1990-06-01 1991-12-02 Ginette Serrero Mammalian adipogenic factors
US20060263774A1 (en) * 2002-11-01 2006-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US10328131B2 (en) 2014-03-13 2019-06-25 Dana-Farber Cancer Institute, Inc. Compositions and methods for regulating pancreatic beta cell function using adipsin
DE102014107380A1 (de) 2014-05-26 2015-11-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Verfahren zur Diagnose einer durch den alternativen Weg des Komplementsystems vermittelten Krankheit oder eines Risikos hierfür

Also Published As

Publication number Publication date
ZA882288B (en) 1988-12-28
DK675388D0 (da) 1988-12-02
EP0287509B1 (de) 1992-09-16
DE3874543T2 (de) 1993-02-04
AU1591388A (en) 1988-11-02
EP0382720A1 (de) 1990-08-22
EP0287509A1 (de) 1988-10-19
EP0382720B1 (de) 1992-09-09
FI894592A7 (fi) 1989-09-28
ATE80465T1 (de) 1992-09-15
EP0382720A4 (en) 1991-01-02
AU606946B2 (en) 1991-02-21
FI894592L (fi) 1989-09-28
NO885360L (no) 1989-02-01
ES2046325T3 (es) 1994-02-01
FI894592A0 (fi) 1989-09-28
WO1988007681A1 (en) 1988-10-06
DK675388A (da) 1988-12-02
JPH02503229A (ja) 1990-10-04
GR3005716T3 (de) 1993-06-07
NO885360D0 (no) 1988-12-01
DE3874543D1 (de) 1992-10-15

Similar Documents

Publication Publication Date Title
ATE269978T1 (de) Verfahren zur bestimmung der prognose eines patienten mit einer neurologischen krankheit
EP1019072A4 (de) Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen
GB8710925D0 (en) Type iii collagen degradation assay
EP0625991A4 (de) Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute.
HARRINGTON et al. The association between lichen sclerosus et atrophicus and HLA‐B40
IL85897A0 (en) Method of diagnosing obesity caused by a genetic abnormality
Simpson et al. Effect of zimelidine, a new antidepressant, on appetite and body weight
ZA92389B (en) Method for detection of anti-rna-antibodies
Björkholm et al. Immunological defects in healthy twin siblings to patients with Hodgkin's disease
Nicholson et al. The creatine kinase reference interval: An assessment of intra-and inter-individual Variation
Nakamura et al. A novel variant of transthyretin (Glu89Lys) associated with familial amyloidotic polyneuropathy
Zschiedrich et al. Urinary kallikrein in normotensive subjects and in patients with essential hypertension
Merluzzi et al. Recovery of the capacity for cytotoxic T cell generation in cyclophosphamide-treated mice by the addition of Lyt-1+ 2− helper cells
SKOUBY Hydroxocobalamin for Initial and Long‐term Therapy for Vitamin B12 Deficiency
Scharf et al. Transverse myelitis with systemic lupus erythematosus
DE3572033D1 (en) Method for diagnosis of a.i.d.s.
Leisti et al. Phenotypic variation in alpha-L-iduronidase deficiency
SU943578A1 (ru) Способ определени суточной дозы гепарина
Goldstein Carbamazepine treatment for stuttering.
DE69028023D1 (de) Verfahren zur Bestimmung des Cholesterins, zum Nachweis von Gefässkrankheiten und zur Anhebung des Anteils an HDL-Cholesterin
SU787995A1 (ru) Способ дифференцировани т и в лимфоцитов человека
Gately et al. Effect of anti-lymphotoxin on cell-mediated cytotoxicity: Evidence for two pathways of cytolysis
Digel et al. Induction of interferon gamma in leucocyte cultures of the peripheral blood of mice
Lijnen et al. Effect of aspirin on renal function and the prostaglandin-kallikrein systems early after myocardial infarction
UA6102A1 (uk) Спосіб визначення індивідуальної чутливості хворих до кемантану при хронічному обструктивному бронхіті